
Shares of Serina Therapeutics Inc (NYSE:SER) rose sharply in pre-market trading after the company announced the FDA has provided written feedback supporting the advancement of SER-252.
Serina Therapeutics shares jumped 25.3% to $7.07 in the pre-market trading session.